The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of January 2022. This month there is one guideline, two technology appraisals and one innovation briefing that impact upon primary care.
The Glaucoma: diagnosis and management guideline has been updated. It covers diagnosing and managing glaucoma in people aged 18 and over. It includes recommendations on testing and referral (case-finding) for chronic open-angle glaucoma and ocular hypertension and on effective diagnosis, treatment and reassessment to stop these conditions progressing. This update reviewed the evidence and recommendations on treatment for ocular hypertension and chronic open-angle glaucoma and organisation of care.
The Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy technology appraisal has been published. This treatment is recommended as an option for treating excessive daytime sleepiness in adults with narcolepsy with or without cataplexy. This recommendation applies only after modafinil and either dexamfetamine or methylphenidate have not worked well enough or are not suitable. It is expected that this medication would normally be requested by a specialist.
The Sodium zirconium cyclosilicate for treating hyperkalaemia technology appraisal has been updated. This treatment is recommended as an option for treating hyperkalaemia in adults under specific criteria. This update takes account that this treatment in now available in both primary and secondary care.
The Smart Peak Flow for monitoring asthma innovation briefing has been published. The briefing notes that Smart Peak Flow could replace mechanical peak flow meters. But evidence is needed on its validation against the current gold standard in peak flow meters, asthma-related outcomes, use and adherence, and the effect on clinical decision making and resource use. These briefings are usually used to guide local commissioning decisions and therefore clinicians should confirm local arrangements for this device.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Drug Safety Update - January 2022||CKS Updates - January 2022 »|